ACTRN12610000179033已完成4 期
A randomised, assessor blind, parallel group comparative trial of NeutraLice Lotion, NeutraLice Advance and Banlice Mousse in the treatment of head lice in children
key Pharmaceuticals Ltd.0 个研究点目标入组 120 人开始时间: 2010年2月26日最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 5 Years 至 12 Years（—）
- 性别
- All
入选标准
- •Male or female primary school-aged children.
- •Presence of live head lice (adults or nymphs) on the hair or scalp. The presence of live lice will be determined from a visual inspection of the hair and scalp, and dry-combing of the hair. Combing will stop immediately once live lice are detected. The presence of lice eggs alone is not a sufficient condition for inclusion in the trial.
- •Available for the duration of the trial.
- •Parent / Guardian have given written informed consent to their child’s participation in the trial.
排除标准
- •History of allergies or adverse reactions to head lice products or the components of the specific products being tested.
- •Treatment with any head lice product in the 4 weeks prior to participation in this trial.
- •Treatment with any head lice product during the trial.
- •Treatment with a head lice comb during the trial if the subject is found to be louse free on the final examination day.
- •Presence of scalp disease(s).
- •If the subject has a sibling in Grade 1-7, who lived at the same residence during the treatment period the sibling must be examined for lice and if infested, enrolled in this study or wet combed out on multiple days.
- •Subjects must have one fixed place of residence during the trial.
研究者
相似试验
已完成
4 期
A randomised, assessor blind, parallel group, comparative trial of the Ovicidal Activity of Three Head Lice Products (NeutraLice Lotion, NeutraLice Advance and Moov Head Lice Solution) After a Single Applicatiohead lice infestationSkin - Dermatological conditionsACTRN12609000884202Key Pharmaceuticals Pty. Ltd.90
尚未招募
3 期
Comparative study between two brands of human menopausal gonadotropin in infertility patientsCTRI/2019/10/021795Bharat serums and Vaccines ltd
进行中（未招募）
1 期
A randomised, assessor-blind, parallel groups, multi-centre, exploratory study assessing the impact of subcutaneous administration of degarelix 2.5 mg on synchronisation of follicle cohort compared to placebo and evaluating the effects of degarelix 2.5 mg started in the mid-luteal or early follicular phase on endometrial receptivity compared to a fixed gonadotrophin releasing hormone antagonist protocol in oocyte donors undergoing controlled ovarian hyperstimulation for assisted reproductive technologies - EASYFIX Exploratory Study Assessing Synchronisation of Follicles with DegarelixPrevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART)MedDRA version: 8.1Level: LLTClassification code 10021926Term: InfertilityEUCTR2006-004684-58-BEFerring Pharmaceuticals A/S80
进行中（未招募）
1 期
A randomised, assessor-blind, parallel groups, multi-centre, exploratory study assessing the impact of subcutaneous administration of degarelix 2.5 mg on synchronisation of follicle cohort compared to placebo and evaluating the effects of degarelix 2.5 mg started in the mid-luteal or early follicular phase on endometrial receptivity compared to a fixed gonadotrophin releasing hormone antagonist protocol in oocyte donors undergoing controlled ovarian hyperstimulation for assisted reproductive technologies - EASYFIX Exploratory Study Assessing Synchronisation of Follicles with DegarelixPrevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART)MedDRA version: 14.1Level: PTClassification code 10021926Term: InfertilitySystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2006-004684-58-ESFerring Pharmaceuticals A/S80
进行中（未招募）
不适用
A randomised, assessor-blind, parallel groups, multi-centre, exploratory study assessing the impact of subcutaneous administration of degarelix 2.5 mg on synchronisation of follicle cohort compared to placebo and evaluating the effects of degarelix 2.5 mg started in the mid-luteal or early follicular phase on endometrial receptivity compared to a fixed gonadotrophin releasing hormone antagonist protocol in oocyte donors undergoing controlled ovarian hyperstimulation for assisted reproductive technologies - EASYFIX Exploratory Study Assessing Synchronisation of Follicles with DegarelixEUCTR2006-004684-58-CZFerring Pharmaceuticals A/S80